MASIMO CORP

Key metrics

Financial performance

Over the last 10 fiscal years MASIMO CORP's revenue grew from $712.90M to $1.53B, a compound annual growth rate of 7.9%. Net profit margin compressed from 43.6% to -9.9% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,510 filings)

Recent press releases

• Masimo Shareholders Approve Acquisition by Danaher2026-05-04

  Katie Szyman, Chief Executive Officer of Masimo, stated: “We thank our shareholders for their strong support of this important milestone for Masimo. The Merger delivers compelling value and positions Masimo for continued global growth as an independent operating company within Danaher’s Diagnostics segment. We look forward to completing this process and, together with Danaher, continuing our mission of developing innovative technologies that empower clinicians to transform patient care.”

• Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study2026-04-28

  _NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns_

• Masimo to be Acquired by Danaher for $180.00 Per Share2026-02-17

  Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”).

• Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 262026-02-12

  _Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)_

• Masimo Announces Select Preliminary 2025 Financial Results2026-01-12

  _Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026_

Similar companies

The largest companies sharing MASIMO CORP's SEC industry classification (electromedical & electrotherapeutic apparatus).